Format

Send to

Choose Destination
J Pharmacol Sci. 2015 Dec;129(4):240-3. doi: 10.1016/j.jphs.2015.09.006. Epub 2015 Nov 17.

Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione.

Author information

1
Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0914, Japan.
2
Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
3
Department of Analytical and Biophysical Chemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
4
Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0914, Japan. Electronic address: mineyuki@pha.u-toyama.ac.jp.
5
Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan. Electronic address: hirokai@gpo.kumamoto-u.ac.jp.

Abstract

Familial amyloid polyneuropathy (FAP) is a genetic, adult-onset, neurodegenerative disorder caused by amyloid formation of transthyretin (TTR), a thyroxine-binding protein. Mutation in TTR causes a propensity of TTR tetramer to dissociate to monomer, which is the first step to amyloidosis. Thus, a drug that can stabilize the tetramer structure will have therapeutic benefit. Here, by virtual screening and biochemical assays, we identified small molecule 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione (L6) that can prevent the dissociation of TTR to monomer. X-ray crystallography reveals that L6 binds to the T4 binding pocket of TTR. These findings show that L6 is a candidate TTR stabilizer.

KEYWORDS:

6-Benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione (L6); Familial amyloid polyneuropathy (FAP); Transthyretin (TTR)

PMID:
26639444
DOI:
10.1016/j.jphs.2015.09.006
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center